Roy Gray is Vice President, Non-Clinical Development of Sudo Biosciences. He was previously Executive Director at Kadence Bio from 2020-2022, leading a multidisciplinary nonclinical team to successfully deliver data packages supporting the initiation of phase 1 clinical studies. Prior to Kadence Bio, Roy held senior positions at GW Pharmaceuticals (acquired by Jazz Pharmaceuticals in 2021), where he led the pharmacology team that contributed to the approval globally of Epidiolex for the treatment of pediatric epilepsy in Dravet, and Lennox–Gastaut Syndromes and Tuberous sclerosis complex. Roy also led parallel neurology / neuropsychiatry programs delivering open INDs for the assessment of cannabinoid-based therapeutics in epilepsy, multiple sclerosis and other related therapeutic areas. Prior to GW Pharmaceuticals, Roy gained expertise at Heptares (now Nxera), GSK, and Medimmune (AZ) in multiple nonclinical disciplines (including in vivo and in vitro pharmacology, electrophysiology), operating in the neuroscience, GI and respiratory therapeutic areas, in small and large molecule drug discovery and development.

Roy holds a BSc (Hons) Pharmacology.